Aripiprazole

Generic Name
Aripiprazole
Brand Names
Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
Drug Type
Small Molecule
Chemical Formula
C23H27Cl2N3O2
CAS Number
129722-12-9
Unique Ingredient Identifier
82VFR53I78
Background

Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...

Indication

Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...

Associated Conditions
Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
Associated Therapies
Monotherapy
Clinical Trials
Related News

Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder

First Posted Date
2011-12-08
Last Posted Date
2011-12-08
Lead Sponsor
Korea University
Target Recruit Count
90
Registration Number
NCT01488266
Locations
🇰🇷

Korean Univ Ansan Hospital; Bucheon St.Mary Hospital; DonggukUniv Gyeongju Hospital; Catholic University of Korea St. Paul's Hospital, Seoul, Korea, Republic of

🇨🇳

Chang Gung Memorial Hospital; Kaohsiung Medical University Chung-ho Memorial Hospital, Taipei, Taiwan

Bergen Psychosis Project 2 - The Best Intro Study

First Posted Date
2011-10-05
Last Posted Date
2020-06-19
Lead Sponsor
Haukeland University Hospital
Target Recruit Count
151
Registration Number
NCT01446328
Locations
🇳🇴

Stavanger University Hospital, Stavanger, Norway

🇦🇹

Medizinische Universität Innsbruck, Innsbruck, Austria

🇳🇴

Haukeland University Hospital, Bergen, Norway

and more 1 locations

Aripiprazole for the Augmentation of Antidepressant Therapy

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Aripiprazole
First Posted Date
2011-09-07
Last Posted Date
2014-05-21
Lead Sponsor
Taiwan Otsuka Pharm. Co., Ltd
Target Recruit Count
300
Registration Number
NCT01429831
Locations
🇨🇳

Chung Shan Medical University Hospital, Taichung, Taiwan

A PET Study in Healthy Volunteers

Phase 1
Completed
Conditions
Depressive Disorder
Interventions
Radiation: [11C]PHNO
Drug: Aripiprazole
First Posted Date
2011-08-29
Last Posted Date
2012-12-17
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
7
Registration Number
NCT01424449
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

Phase 3
Completed
Conditions
Tourette's Disorder
Interventions
Drug: Placebo
Drug: Aripiprazole
First Posted Date
2011-08-17
Last Posted Date
2021-10-07
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
83
Registration Number
NCT01418352

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Phase 3
Completed
Conditions
Tourette's Disorder
Interventions
Drug: Placebo
Drug: Aripiprazole
First Posted Date
2011-08-17
Last Posted Date
2021-10-07
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
135
Registration Number
NCT01418339

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Phase 3
Completed
Conditions
Tourette's Disorder
Interventions
Drug: Aripiprazole
First Posted Date
2011-08-15
Last Posted Date
2021-10-07
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
170
Registration Number
NCT01416441

Aripiprazole and Resistant Postpartum Depression

Phase 3
Completed
Conditions
Postpartum Depression
Interventions
Drug: aripiprazole
First Posted Date
2011-06-30
Last Posted Date
2016-03-17
Lead Sponsor
Lawson Health Research Institute
Target Recruit Count
10
Registration Number
NCT01386086
Locations
🇨🇦

Regional Mental Health Care, London, Ontario, Canada

A Study of Safety and Tolerability in Subjects With Schizophrenia

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: Aripiprazole
Drug: LY2140023
First Posted Date
2011-05-16
Last Posted Date
2022-09-14
Lead Sponsor
Denovo Biopharma LLC
Target Recruit Count
75
Registration Number
NCT01354353
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States

Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

Not Applicable
Completed
Conditions
Hyperprolactinemia
Interventions
Drug: Aripiprazole
Drug: Placebo
First Posted Date
2011-04-19
Last Posted Date
2019-09-27
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
60
Registration Number
NCT01338298
Locations
🇺🇸

Maryland Psychiatric Research Center, Catonsville, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy